Derma Pharma Pty Ltd is an Australian biotechnology company developing dermatology therapeutics for inflammatory skin diseases. The company is anchored by Algavio, a proprietary standardised multi-compound extract derived from Arthrospira maxima, with an initial commercial focus on OTC acne and future expansion across eczema, psoriasis and other inflammatory skin conditions. 

​​

Gaps in the acne, psoriasis, and eczema markets remain unaddressed, creating a vital

opportunity for innovation.

​

Core Focus: Addressing unmet medical needs in dermatological conditions, initially targeting acne, which affects 9.4% of the global population. Initial commercial focus is the US acne market, using Amazon as a validation channel to generate real-world consumer, safety and usage data before broader channel expansion.

​

Future skin solutions will be focused on psoriasis and eczema.

​

Innovative Technology: Leveraging our proprietary ALGAVIO ingredient to innovate and revolutionise acne treatments. Acne ranks as the eighth most prevalent disease worldwide, offering a significant market opportunity. Psoriasis and eczema products will follow the successful launch of the acne range.

"ALGAVIO innovates and revolutionises acne treatments."

​​​

Mission: We are redefining dermatology with next-generation, science-led skincare that prioritises safety, efficacy, and sustainability.

Our Breakthrough: Algavio is the result of years of research and biotech innovation, delivering a safe, non-toxic solution to chronic skin conditions including acne, eczema, and psoriasis.

Our Vision: To create a global skin health platform with patented, evidence-based actives that improve lives and challenge the status quo of dermatological care.

​

Capital Raise and Exit Strategy

Derma Pharma is conducting a Seed Round raising $USD2M via a SAFE instrument. Funds will be used to conduct the necessary Research & Development to test and formulate the initial acne range and develop the market entry strategy.

 

We plan to build the business to a stage where a Trade Sale or an IPO on either the ASX, TSX or AIM is possible within a 4 – 5 year period.